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Background: Clinical trials of PI monotherapy indicate that most participants maintain viral suppression and
emergent protease resistance is rare. However, outcomes among patients receiving PI monotherapy for clinical
reasons, such as toxicity or adherence issues, are less well studied.
Methods: An observational study of patients attending an HIV treatment centre in London, UK, who had received
PI monotherapy between 2004 and 2013, was conducted using prospectively collected clinical data and geno-
typic resistance reports. Survival analysis techniques were used to examine the times to virological failure and
treatment discontinuation.
Results: Ninety-five patients had PI monotherapy treatment for a median duration of 126 weeks. Virological fail-
ure occurred during 64% of episodes and 8% of patients developed emergent protease mutations. We estimate
failure occurs in half of episodes within 2 years following initiation. Where PI monotherapy was continued follow-
ing virological failure, 68% of patients achieved viral re-suppression. Despite a high incidence of virological failure,
many patients continued PI monotherapy and 79% of episodes were ongoing at the end of the study. The type of
PI used, the presence of baseline protease mutations and the plasma HIV RNA at initiation did not have a signifi-
cant impact on treatment outcomes.
Conclusions: There was a higher incidence of virological failure and emerging resistance in our UK clinical setting
than described in PI monotherapy clinical trials and other European observational studies. Despite this, many
patients continued PI monotherapy and regained viral suppression, indicating this strategy remains a viable
option in certain individuals following careful clinical evaluation.
Introduction
PI monotherapy is an appealing option in a subset of patients for
whom combination ART (cART) is unsuitable for clinical reasons,
such as adverse effects associated with nucleoside reverse tran-
scriptase inhibitors, interactions with other medication and
adherence issues. Combination regimens may be more difficult
to adhere to because of reduced tolerability, increased pill burden
or demands such as the timing of doses. Theoretically, modern
boosted PIs are good candidates for use as monotherapy as
this class is known to have a high genetic barrier to resistance
following viral failure, requiring several mutations before pheno-
typic drug susceptibility is significantly reduced.1,2 In an era
when patients will initiate treatment earlier and can expect to
be taking therapy for decades, other potential advantages of PI
monotherapy include the avoidance of toxicity and preservation
of long-term treatment options.3,4
Randomized controlled trials investigating PI monotherapy as
a maintenance strategy indicate that most participants maintain
viral suppression and the emergence of resistance-associated
protease mutations is rare. Trials showed a wide range of viro-
logical failure when a threshold of plasma HIV RNA .50 copies/mL
was used, varying from 5% to 53% over 48 or 96 week follow-up
periods.5 – 12 In PIVOT, the largest PI monotherapy trial to date,
which included 296 patients in the monotherapy arm, 31%
experienced virological failure.5 In the MONARK trial,13 the only
PI monotherapy trial of ART-naive patients who were viraemic
at baseline, the proportion that did not achieve sustained viro-
logical suppression was 33% by week 48 and 54% by week 96.
Most trial protocols mandate a switch to cART in the case of
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virological failure and so there is little information on virological
re-suppression on monotherapy. In the PIVOT study, of the
93 patients with virological rebound, 22 had spontaneously
re-suppressed on subsequent testing and a further two re-sup-
pressed after changing the PI but remaining on monotherapy.5
There were considerable differences among trials in the definition
of emergent mutations, with some reporting all protease muta-
tions and others only the mutations related to the specific PI
agent used for monotherapy. The proportion of trial participants
that developed emergent protease mutations when PI monother-
apy was used as a maintenance strategy was on average ,1%
(range 0%–2.3%).5 – 12,14,15 Emergent resistance resulted in the
loss of future PI options in 1% of patients in the PIVOT trial.5
There was a higher proportion of emergent protease mutations,
6%, in the MONARK trial, where PI monotherapy was used as first-
line therapy.13
However, the results of these trials may not be generalizable to
patients who receive PI monotherapy for clinical reasons. Trial par-
ticipants had mostly already achieved virological suppression, did
not have pre-existing protease resistance mutations and presum-
ably were considered likely to adhere to a study protocol.
Virological failure was not usually reported beyond 96 weeks,
which limits the ability to extrapolate the results to the long-term
success of this approach. PI monotherapy may not be as success-
ful in patients with a history of treatment failure. The EARNEST
study evaluated lopinavir monotherapy in patients who had failed
first-line cART in resource-limited settings and found that 18%
developed intermediate or high-level lopinavir resistance.16
Furthermore, intensification to cART following virological failure
would only be possible if the patient could tolerate cART, which
may not be the case in a real-world clinical setting. We conducted
a review of patients who had received PI monotherapy at our cen-
tre in order to determine the clinical effectiveness of this strategy,
the emergence of resistance and factors associated with viro-
logical failure. We show that virological failure and emergent pro-
tease mutations are more common in our cohort than in
randomized controlled trials and other observational studies of
European clinical settings.
Methods
Study design
A retrospective analysis of 10 years of prospectively collected data was
conducted at a large HIV treatment centre in central London, UK. The
study population was selected from HIV-1-positive patients attending
the clinic between 1 January 2004 and 31 December 2013. Patients
were included in the study if they were aged 16 years or over and had
received at least 30 days of monotherapy with a boosted PI, and were
excluded if they had been enrolled in a clinical trial of PI monotherapy.
Data on demographics, antiretroviral treatment history, HIV RNA measure-
ments and genotypic resistance testing were gathered from clinic records
and the laboratory information management system.
Laboratory methods
HIV-1 RNA quantification and genotyping were performed using validated
in-house methods.17 Archived genotypic resistance reports were available
from 2004 onwards. The Stanford HIV Drug Resistance Database2 was
used to determine HIV-1 subtype, identify baseline and emergent prote-
ase resistance-associated mutations and evaluate the impact of emer-
gent mutations.
Primary and secondary endpoints
The primary endpoint was time from initiation of PI monotherapy to
virological failure, which was defined as either after persistently detectable
viraemia throughout the first 6 months of the PI monotherapy episode
or virological rebound (two consecutive plasma samples with HIV RNA
.50 copies/mL or a single plasma sample with HIV RNA .1000 copies/mL)
at any point following viral suppression (at least one sample with HIV RNA
,50 copies/mL). Other outcomes of interest were the times to: (i) viral
re-suppression on PI monotherapy (viral suppression following virological
failure); (ii) treatment discontinuation (switch to cART); and (iii) the emer-
gence of protease resistance and loss of future PI therapeutic options
(development of intermediate or high-level resistance to any PI was con-
sidered to be loss of that agent).
Statistical analysis
Kaplan–Meier survival curves were plotted to describe the distribution of
the times to virological failure and treatment discontinuation. The patients
were stratified according to the presence of protease mutations at PI
monotherapy initiation, baseline HIV RNA and the type of PI agent, to
examine the effects of these factors. If patients had received consecutive
periods of PI monotherapy with different PIs, i.e. changed PI agent but
remained on PI monotherapy, this was considered as one continuous PI
monotherapy episode for the main analyses. The individual periods of PI
monotherapy with different agents were only considered separately
when examining the effect of the type of PI on the virological outcome.
The associations between factors and time to an event were tested
using the log rank test, except when assessing type of PI, when Cox regres-
sion with a frailty term for patient was used to acknowledge the clustering
of periods of different PI treatment for some patients. A univariate Cox
regression analysis was performed to look for factors associated with viro-
logical failure. If any variables were significant then these would be
included in a multivariate Cox regression analysis. Stata/IC 14 software
(StataCorp LP, College Station, TX, USA) was used for all statistical analyses.
Ethics
In the UK retrospectively obtained anonymized NHS data do not require
patient consent.
Results
Study population
One hundred and twenty-three patients received PI monotherapy
at the study centre during the 10 year observation period.
Twenty-eight patients were excluded from the analysis as they
had participated in a PI monotherapy trial where use of PI mono-
therapy was not driven by clinical circumstances. A total of 95
patients that had received PI monotherapy for clinical reasons
remained for the final analysis. Their characteristics are shown
in Table 1. The HIV-1 subtype was known for 74 patients, 40
(54%) of whom had subtype B infection. The other subtypes
were A (six patients, 8% of known study subtypes), C (nine patients,
12%), CRF01_AE (eight patients, 11%), CRF02_AG (five patients, 7%)
and 8% other subtypes (two patients harboured subtype D, and
subtypes G, J and K were each found in one patient).
PI monotherapy episodes
PIs used for monotherapy were darunavir, atazanavir and lopina-
vir, all boosted with ritonavir. Seventeen patients received two
different PIs as monotherapy at separate times during the
PI monotherapy
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observation period and one patient received three different
agents, giving a total of 114 individual periods of PI monotherapy.
The PI agent was changed during an uninterrupted episode of
monotherapy in 17 cases, and these were treated as continuous
PI monotherapy episodes. The reasons for changing PI were not
known; 12 changed PI while virally suppressed and 5 while vir-
aemic. Overall, 97 continuous PI monotherapy episodes were
included in the analysis (two patients had two non-consecutive
PI monotherapy episodes each). The median episode duration
was 126 weeks (IQR¼96–174). At the end of the study period,
77 PI monotherapy episodes were ongoing, and 57 of those had
viral suppression at the last HIV RNA measurement of the study
period. No patients were lost to follow-up.
Primary endpoint
Virological failure occurred during follow-up in 64% (62/97) of epi-
sodes. Four were due to persistent viraemia and 58 had
rebounded following a period of viral suppression. The overall
time-to-event analysis is shown in Figure 1. We estimate from
the Kaplan –Meier curves that virological failure occurs within
2 years for around half of episodes. The presence of baseline pro-
tease mutations (P¼0.84), the baseline plasma HIV RNA
(P¼0.90) and the type of PI (P¼0.47) did not affect the rate of
virological failure (Figure 2). Univariate analyses were performed
for sex, age, sexual orientation, ethnicity, nadir CD4 count, base-
line CD4 count, number of previous ART regimens, ARTexperience,
PI experience, detectable HIV RNA at PI monotherapy initiation,
and duration of viral suppression prior to PI monotherapy. No vari-
ables were found to be significantly associated with virological
failure and so a multivariable analysis was not performed.
Secondary outcomes
Viral re-suppression
Viral re-suppression on PI monotherapy, without changing
therapy, occurred in 38 episodes. This represents 61% (38/62)
of all virological failure episodes and 68% (38/56) of those
episodes in which PI monotherapy was continued for at least
1 month following virological failure. The median time to viral
re-suppression after the initial date of virological failure was
14 weeks (IQR¼9–31), as shown in Figure 3. The median level
Table 1. Baseline characteristics
Male, n (%) 67 (71)
Age (years), median (IQR) 44 (38–48)
MSM, n (%) 46 (48)
Ethnicity, n (%)
white 50 (53)
black 38 (40)
other/unknown 7 (7)
Nadir CD4 count (cells/mm3), median (IQR) 180 (70–250)
CD4 count at PI monotherapy initiation (cells/mm3), median (IQR) 455 (290–640)
Number of previous ART regimens prior to PI monotherapy, median (IQR) 4 (2–7)
ART experienced before PI monotherapy, n (%) 92 (97)
PI experienced before PI monotherapy, n (%) 77 (81)
Detectable plasma HIV RNA .50 copies/mL at start of episode, n (%) 40 (41)
Plasma HIV RNA at start of episode for the 40 episodes that started during viraemia (copies/mL), median (IQR) 6500 (510–46000)
Duration of viral suppression prior to PI monotherapy for the 57 episodes that started during
viral suppression (weeks), median (IQR)
352 (181–555)
Follow-up time (weeks), median (IQR) 143 (118–186)
Denominators of 95 patients and 97 episodes.
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Figure 1. Overall treatment outcomes.
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of HIV-1 RNA at virological failure was 4100 copies/mL
(IQR¼760–16500) in those patients who subsequently had viral
re-suppression, compared with 3150 copies/mL (IQR¼955–23750)
in those who did not re-suppress.
Treatment discontinuation
Treatment was discontinued during follow-up in 21% (20/97) of PI
monotherapy episodes. From Figure 1 we see that around a quar-
ter of treatment episodes are discontinued within 4 years. In each
case, the regimen was intensified to cART. There was some over-
lap between virological failure and treatment discontinuation, as
15 episodes during which virological failure occurred also resulted
in a switch to cART. The reasons for treatment discontinuation in
the remaining five episodes with sustained viral suppression were
not known.
Genotypic protease resistance
Genotypic resistance tests performed prior to PI monotherapy
were available for 60 patients, of whom 29 had pre-existing pro-
tease mutations. Five patients had major mutations at baseline
and 28 had minor mutations. Thirty-six patients had tests avail-
able from both before and after starting PI monotherapy. Eight
patients (8.4% of total cohort) had emergent protease mutations
in repeat testing that had not been detected before PI monother-
apy (Table 2). A further 14 patients had tests obtained after com-
mencing PI monotherapy but no baseline test was available for
comparison. One of these patients had protease mutations
(Patient 9 in Table 2). Six patients (6.3% of total) developed inter-
mediate or high-level resistance to at least one PI, of whom four
developed intermediate or high-level resistance to the PI used for
monotherapy, rendering that agent unusable for future therapy
(Patients 4, 5, 8 and 9 in Table 2). Loss of future PI options resulted
in a switch to cART, except for Patient 9, who had developed high-
level resistance to atazanavir during atazanavir monotherapy but
achieved virological suppression after switching to darunavir
monotherapy. Of the five patients with pre-existing major prote-
ase mutations, two went on to develop emergent mutations
(Patients 7 and 8 in Table 2). The other three patients with
major baseline mutations were all PI experienced and had com-
menced PI monotherapy during viral suppression. One had a sin-
gle major mutation (N88S) and two minor mutations (L10V and
L33I) at baseline but remained virally suppressed on darunavir
and then lopinavir monotherapy throughout follow-up, and the
other two also had a single major mutation at baseline (M46L
with minor mutations L63P, V77I/V and I93L, and L90M alone).
Both experienced virological failure on atazanavir monotherapy
but repeat resistance testing did not reveal any new mutations.
They remained on PI monotherapy with viral suppression at the
end of the study period.
Discussion
Virological failure was common in this real-world setting and
occurred in two-thirds of PI monotherapy episodes. Our patients
had less favourable resistance profiles and higher HIV RNA levels
at baseline than most PI monotherapy trial participants. They also
had a higher incidence of emergent protease mutations and
greater loss of future PI options. Despite this, over half the cohort
ended the observation period continuing on PI monotherapy with
viral suppression.
This is the first study, to our knowledge, to investigate the real-
life use of PI monotherapy in a clinical setting where the use of
PI-containing cART as first line is uncommon. There have been
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Figure 2. Univariate analysis of virological failure by (a) baseline protease
mutations, (b) baseline plasma HIV-1 RNA viral load (detectable,
.50 copies/mL; undetectable, ,50 copies/mL) and (c) PI type. This
figure appears in colour in the online version of JAC and in black and
white in the print version of JAC.
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other observational studies in Spain and France, where PI-
containing cART is more frequently used as first-line treatment,
and our cohort otherwise had comparable baseline characteris-
tics to those studies, with a preponderance of male patients,
white ethnicity, MSM mode of transmission and subtype B
infection, all typical of a European setting.18 – 22 Another similarity
was that over three-quarters of patients were PI experienced prior
to receiving monotherapy. Our cohort had a median baseline CD4
count of 455 cells/mm,3 lower than the averages reported in the
other clinical studies, which were between 541 and 608.18,19,21 – 23
The median nadir CD4 count of 180 was within the range found in
the clinical studies (medians were between 155 and 238).18 – 21,23
We did not find an independent association between CD4 count
and failure, as did four of the observational studies.18,20,21,23
One study found an association between a nadir CD4 of
,200 cells/mm3 and virological failure.19 Two of the trials,
PROTEA14 and MODAt,15 found a low CD4 count was related to
outcome, while MONET7 did not find an independent association.
There were some clear differences between our findings and
the other analyses of PI monotherapy in clinical practice. In the
other studies, plasma HIV RNA had to be fully suppressed for at
least 6 months before PI monotherapy was commenced,
whereas 40% of our patients were viraemic at PI monotherapy
initiation.18 – 23 We only investigated patients prescribed PI mono-
therapy for clinical reasons but one large multicentre study of clin-
ical practice did not exclude PI monotherapy trial participants.19
When the indications for PI monotherapy were cited they were
commonly treatment simplification or patient preference.18,21– 23
This is in line with European and Spanish guidelines, which since
2009 cite PI monotherapy as an alternative strategy in the
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Figure 3. Viral re-suppression following virological failure.
Table 2. Patients with emergent protease mutations on PI monotherapy
No. PI agent
HIV RNA
at start
(copies/mL)
Previous
PI use
Protease
mutations before
PI monotherapy
Emergent
protease
mutations
Outcome of PI
monotherapy
Loss of future PI options
(level of resistancea)
1 DRV 0 none none minor: 10I VF, but ongoing PI
monotherapy (last
RNA undetectable)
no
2 DRV 780 LPV none minor: 35D/G VF, but ongoing PI
monotherapy (last
RNA undetectable)
no
3 DRV 350000 ATV none minor: 11I/V VF, but ongoing
PI monotherapy
(last RNA
100000 copies/mL)
no
4 LPV 420 SQV none major: 46I, 84V
minor: 10F
VF and switched to cART ATV, FPV, IDV, NFV, SQV (high)
LPV, TPV (intermediate)
5 ATV 1700 ATV none major: 50L, 90M
minor: 71V, 73S
VF and switched to cART ATV, NFV, SQV (high)
IDV (intermediate)
6 LPV 0 SQV, NFV minor: 10I, 58E major: 50L VF and switched to cART ATV (high)
7 LPV 360 none major: 50L, 88S
minor: 33F, 71V
major: 82A/V VF and switched to cART IDV (intermediate)
8 DRV 0 LPV major: 46I
minor: 10F, 74A/P
major: 32I, 47V VF and switched to cART FPV, IDV, LPV, NFV, TPV (high)
ATV, DRV (intermediate)
9 ATV then DRV 0 SQV, LPV missing data major: 24I, 50L
minor: 71T
VF on ATV, switch to
DRV ongoing PI
monotherapy (last
RNA undetectable)
ATV (high)
VF, virological failure; DRV, darunavir; LPV, lopinavir; ATV, atazanavir; SQV, saquinavir; NFV, nelfinavir; FPV, fosamprenavir; IDV, indinavir; TPV, timprenavir.
aStanford HIV Drug Resistance Database interpretation.
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management of selected patients.24,25 French national guidelines
have been more conservative, in 2010 deeming PI monotherapy
to be inadequate, and in the 2013 iteration indicating that this
strategy can be considered on a case-by-case basis.26,27
However, UK guidelines either did not mention PI monotherapy
or expressly recommended against its use throughout the
10 year period applicable to the present study.28 PI monotherapy
is not generally considered an acceptable treatment option in the
UK unless there are extenuating circumstances that preclude the
use of cART.29 It is our experience that such scenarios where PI
monotherapy is employed include severely ill patients receiving
intensive care who require a regimen with minimal systemic tox-
icity to control viral replication,30 or a patient struggling to comply
with a more complex regimen where PI monotherapy is used as a
holding strategy while further support and adherence interven-
tions are attempted. A limitation of this study is the lack of com-
plete data on the reasons for PI monotherapy and subsequent
management decisions. However, we believe these reflect prac-
tical choices related to adherence and toxicity issues.
Previous clinical practice studies reported 48 week virological
failure rates of 4%,22 10%,21 14%18 and 31%.20 The cumulative
proportion of episodes with virological failure in this study was
around 30% by 48 weeks and around 50% by 2 years. A reason
for the higher risk of virological failure than in most other studies,
particularly in comparison with trial participants, may be that
our cohort was less likely to adhere to therapy. Virological
re-suppression was common in our study when patients
remained on PI monotherapy following failure, suggesting that
adherence was the main determinant of loss of viral control,
and not lack of drug potency. The HIV-1 RNA level at virological
failure did not differ significantly between those who did
and did not go on to experience viral re-suppression. The phenom-
enon of re-suppression has also been observed amongst first-line
cART-treated patients in resource-limited settings.31 Continuation
of monotherapy despite virological failure at our centre probably
reflects a pragmatic clinical decision based on concerns about
adherence and dosing/toxicity issues associated with alternative
regimens.
In the three clinical studies reporting baseline genotypes, the
prevalence of major protease mutations was between 3% and
7% prior to PI monotherapy, similar to the 5% baseline prevalence
in this study.19,21,22 There was considerable variation in the fre-
quency of genotypic resistance testing following virological failure.
Between 20% and 66% of virological failure patients in the clinical
studies had subsequent resistance testing, compared with 80% in
our study. There were also differences in the reporting of muta-
tions across studies. These two factors complicate comparisons
of prior estimates of emergent mutations in clinical settings,
which ranged from 0.4% to 2.2%, with our data (8%).18 – 23
There was no significant difference in study endpoints when the
cohort was stratified according to baseline protease mutations,
HIV RNA at initiation or PI agent. Two clinical practice studies
found that a shorter period of virological suppression prior to PI
monotherapy was associated with increased risk of virological fail-
ure.19,20 One of these also found that virological failure and treat-
ment failure were more likely to occur in patients receiving
atazanavir monotherapy, compared with those on lopinavir or
darunavir.20 Another found lopinavir was associated with a
greater risk of treatment discontinuation than darunavir; how-
ever, the follow-up period was much longer in this group.18 A
further study of similar size to ours did not find any significant pre-
dictors of virological failure.21 One limitation of the present study
is the relatively small sample size that could have resulted in insuf-
ficient statistical power to detect small differences among sub-
groups. However, our findings are in line with a large Spanish
study, which did not find any significant effect of minor pre-
existing mutations, PI agent or duration of previous viral suppres-
sion on the rates of virological failure in patients without major
baseline protease mutations commencing either darunavir or
lopinavir monotherapy.23
An advantage of the present study is that it investigates a real-
world clinical setting with a pragmatic approach to the use of PI
monotherapy in patients with less favourable baseline character-
istics. However, these same attributes could limit the external val-
idity for other settings in which PI monotherapy is to be used in
stable patients with virological suppression and a good history
of treatment engagement. We found high rates of virological fail-
ure but that if PI monotherapy was continued then virological
re-suppression was often achieved. Emergent resistance was
also more common than previously reported, as was the loss of
future PI options. Despite this, the majority of PI monotherapy epi-
sodes were ongoing at the end of this study and over half were
ongoing with viral suppression. Some of the discrepancies in out-
comes compared with other studies may be a result of a longer
observation period, thus capturing more events. It may be that
prolonged follow-up of several years is required to understand
the true outcomes of PI monotherapy in a clinical setting.
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